Immunological therapies involving the use of monoclonal antibodies in renal transplant rejection

The kidney is an extremely important organ, whose main activity is blood filtration, being responsible for the excretion of undesirable substances in the body. Whenever there is a failure or injury in this organ either due to infections and/ or pathologies, loss of functional capacity may occur, req...

Descripción completa

Detalles Bibliográficos
Autores: Oliveira, Francisca Lourenço de, Gonçalves, Kelly Mayne de Oliveira Gonçalves, Berro, Elaine Cristina, Ugrinovich, Leila Aidar, Simioni, Patricia Ucelli
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:Brasil
Institución:Associação Brasileira de Transplante de Órgãos (ABTO)
Repositorio:Brazilian Journal of Transplantation
Idioma:portugués
OAI Identifier:oai:ojs3.emnuvens.com.br:article/8
Acceso en línea:https://bjt.emnuvens.com.br/revista/article/view/8
Access Level:acceso abierto
Palabra clave:Transplantes
Antígenos
Imunossupressores
Anticorpos Monoclonais
Transplantation
Antigens
Immunosuppressive Agents
Monoclonal Antibodies
id BR_ae3c2ecfe33f86f04fca224098ce9986
oai_identifier_str oai:ojs3.emnuvens.com.br:article/8
network_acronym_str BR
network_name_str Brasil
repository_id_str
spelling Immunological therapies involving the use of monoclonal antibodies in renal transplant rejectionTERAPIAS IMUNOLÓGICAS ENVOLVENDO O USO DE ANTICORPOS MONOCLONAIS NA REJEIÇÃO DE TRANSPLANTES RENAISTransplantesAntígenosImunossupressoresAnticorpos MonoclonaisTransplantationAntigensImmunosuppressive AgentsMonoclonal AntibodiesThe kidney is an extremely important organ, whose main activity is blood filtration, being responsible for the excretion of undesirable substances in the body. Whenever there is a failure or injury in this organ either due to infections and/ or pathologies, loss of functional capacity may occur, requiring hemodialysis. In more severe cases, transplantation is prioritized. The most common type of graft is allogeneic performed between individuals of the same species, and although there is partial compatibility between the recipient and the donor, there are risks and cases of rejection; so the use of immunosuppressants is essential, involving the use of both conventional and biological therapies. Thus, biological therapies are becoming an alternative treatment for several patients, and the use of monoclonal antibodies is promising, with possible reduction in the dose of immunosuppressant, and reduction of severe side effects. On the market, Muromonab, Basiliximab and Alentuzumab are currently used as therapy in kidney transplanted recipients. The significant decrease in rejection in kidney transplant recipients is partly associated with these biological treatments.O rim é um órgão de extrema importância, sendo responsável pela excreção de substâncias indesejáveis para o organismo. Quando há falha ou injúria desse órgão, seja por infecções e/ou patologias, pode ocorrer perda da capacidade funcional, com necessidade de hemodiálise. Em casos mais graves, é priorizada a realização de transplante. O tipo de enxerto mais realizado é o alogênico, feito entre indivíduos da mesma espécie; embora haja compatibilidade parcial entre receptor e doador, há riscos e casos de rejeição. Nesses casos, o uso de imunossupressores é imprescindível, envolvendo o uso de terapias convencionais e terapias biológicas. Dessa forma, as terapias biológicas vêm se tornando um tratamento alternativo para diversos pacientes, e a utilização de anticorpos monoclonais mostra-se promissora, com possível diminuição na dose dos imunossupressores e redução de efeitos colaterais severos. No mercado, atualmente, Muromonabe, Basiliximabe e Alentuzumabe são utilizados como terapia para transplantados renais. A diminuição significativa de rejeição nos transplantados renais está associada, em parte, a esses tratamentos biológicos.Associação Brasileira de Transplante de Órgãos (ABTO)2021-09-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://bjt.emnuvens.com.br/revista/article/view/810.53855/bjt.v24i1.8Brazilian Journal of Transplantation; Vol. 24 No. 1 (2021); 44 - 50Brazilian Journal of Transplantation; v. 24 n. 1 (2021); 44 - 502764-1589reponame:Brazilian Journal of Transplantationinstname:Associação Brasileira de Transplante de Órgãos (ABTO)instacron:ABTOporhttps://bjt.emnuvens.com.br/revista/article/view/8/6info:eu-repo/semantics/openAccessOliveira, Francisca Lourenço de Gonçalves, Kelly Mayne de Oliveira GonçalvesBerro, Elaine Cristina Ugrinovich, Leila Aidar Simioni, Patricia Ucelli 2021-10-07T13:29:48Zoai:ojs3.emnuvens.com.br:article/8Revistahttps://bjt.emnuvens.com.br/revistaONGhttps://bjt.emnuvens.com.br/revista/oaibjt@abto.org.brhttps://doi.org/10.53855/2764-15892764-1589opendoar:2021-10-07T13:29:48Brazilian Journal of Transplantation - Associação Brasileira de Transplante de Órgãos (ABTO)false
dc.title.none.fl_str_mv Immunological therapies involving the use of monoclonal antibodies in renal transplant rejection
TERAPIAS IMUNOLÓGICAS ENVOLVENDO O USO DE ANTICORPOS MONOCLONAIS NA REJEIÇÃO DE TRANSPLANTES RENAIS
title Immunological therapies involving the use of monoclonal antibodies in renal transplant rejection
spellingShingle Immunological therapies involving the use of monoclonal antibodies in renal transplant rejection
Oliveira, Francisca Lourenço de
Transplantes
Antígenos
Imunossupressores
Anticorpos Monoclonais
Transplantation
Antigens
Immunosuppressive Agents
Monoclonal Antibodies
title_short Immunological therapies involving the use of monoclonal antibodies in renal transplant rejection
title_full Immunological therapies involving the use of monoclonal antibodies in renal transplant rejection
title_fullStr Immunological therapies involving the use of monoclonal antibodies in renal transplant rejection
title_full_unstemmed Immunological therapies involving the use of monoclonal antibodies in renal transplant rejection
title_sort Immunological therapies involving the use of monoclonal antibodies in renal transplant rejection
dc.creator.none.fl_str_mv Oliveira, Francisca Lourenço de
Gonçalves, Kelly Mayne de Oliveira Gonçalves
Berro, Elaine Cristina
Ugrinovich, Leila Aidar
Simioni, Patricia Ucelli
author Oliveira, Francisca Lourenço de
author_facet Oliveira, Francisca Lourenço de
Gonçalves, Kelly Mayne de Oliveira Gonçalves
Berro, Elaine Cristina
Ugrinovich, Leila Aidar
Simioni, Patricia Ucelli
author_role author
author2 Gonçalves, Kelly Mayne de Oliveira Gonçalves
Berro, Elaine Cristina
Ugrinovich, Leila Aidar
Simioni, Patricia Ucelli
author2_role author
author
author
author
dc.subject.por.fl_str_mv Transplantes
Antígenos
Imunossupressores
Anticorpos Monoclonais
Transplantation
Antigens
Immunosuppressive Agents
Monoclonal Antibodies
topic Transplantes
Antígenos
Imunossupressores
Anticorpos Monoclonais
Transplantation
Antigens
Immunosuppressive Agents
Monoclonal Antibodies
description The kidney is an extremely important organ, whose main activity is blood filtration, being responsible for the excretion of undesirable substances in the body. Whenever there is a failure or injury in this organ either due to infections and/ or pathologies, loss of functional capacity may occur, requiring hemodialysis. In more severe cases, transplantation is prioritized. The most common type of graft is allogeneic performed between individuals of the same species, and although there is partial compatibility between the recipient and the donor, there are risks and cases of rejection; so the use of immunosuppressants is essential, involving the use of both conventional and biological therapies. Thus, biological therapies are becoming an alternative treatment for several patients, and the use of monoclonal antibodies is promising, with possible reduction in the dose of immunosuppressant, and reduction of severe side effects. On the market, Muromonab, Basiliximab and Alentuzumab are currently used as therapy in kidney transplanted recipients. The significant decrease in rejection in kidney transplant recipients is partly associated with these biological treatments.
publishDate 2021
dc.date.none.fl_str_mv 2021-09-07
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://bjt.emnuvens.com.br/revista/article/view/8
10.53855/bjt.v24i1.8
url https://bjt.emnuvens.com.br/revista/article/view/8
identifier_str_mv 10.53855/bjt.v24i1.8
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://bjt.emnuvens.com.br/revista/article/view/8/6
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Associação Brasileira de Transplante de Órgãos (ABTO)
publisher.none.fl_str_mv Associação Brasileira de Transplante de Órgãos (ABTO)
dc.source.none.fl_str_mv Brazilian Journal of Transplantation; Vol. 24 No. 1 (2021); 44 - 50
Brazilian Journal of Transplantation; v. 24 n. 1 (2021); 44 - 50
2764-1589
reponame:Brazilian Journal of Transplantation
instname:Associação Brasileira de Transplante de Órgãos (ABTO)
instacron:ABTO
instname_str Associação Brasileira de Transplante de Órgãos (ABTO)
instacron_str ABTO
institution ABTO
reponame_str Brazilian Journal of Transplantation
collection Brazilian Journal of Transplantation
repository.name.fl_str_mv Brazilian Journal of Transplantation - Associação Brasileira de Transplante de Órgãos (ABTO)
repository.mail.fl_str_mv bjt@abto.org.br
_version_ 1853663431580712960
score 15.301603

Similares en LA Referencia